GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors

After binding to enhancer elements, transcription factors require transcriptional coactivator proteins to mediate their stimulation of transcription initiation. A search for possible coactivators for steroid hormone receptors resulted in identification of glucocorticoid receptor interacting protein 1 (GRIP1). The complete coding sequence for GRIP1, isolated from a mouse brain cDNA library, contains an open reading frame of 1,462 codons. GRIP1 is the probable ortholog of the subsequently identified human protein transcription intermediary factor 2 (TIF2) and is also partially homologous to steroid receptor coactivator 1 (SRC-1). The full-length GRIP1 interacted with the hormone binding domains (HBDs) of all five steroid receptors in a hormone-dependent manner and also with HBDs of class II nuclear receptors, including thyroid receptor alpha, vitamin D receptor, retinoic acid receptor alpha, and retinoid X receptor alpha. In contrast to agonists, glucocorticoid antagonists did not promote interaction between the glucocorticoid receptor and GRIP1. In yeast cells, GRIP1 dramatically enhanced the transcriptional activation function of proteins containing the HBDs of any of the above-named receptors fused to the GAL4 DNA binding domain and thus served as a transcriptional coactivator for them. This finding contrasts with previous reports of TIF2 and SRC-1, which in mammalian cells enhanced the transactivation activities of only a subset of the steroid and nuclear receptors that they physically interacted with. GRIP1 also enhanced the hormone-dependent transactivation activity of intact glucocorticoid receptor, estrogen receptor, and mineralocorticoid receptor. Experiments with glucocorticoid receptor truncation and point mutants indicated that GRIP1 interacted with and enhanced the activity of the C-terminal AF-2 but not the N-terminal AF-1 transactivation domain of the glucocorticoid receptor. These results demonstrate directly that AF-1 and AF-2 domains accomplish their transactivation activities through different mechanisms: AF-2 requires GRIP1 as a coactivator, but AF-1 does not.

[1]  T. Butt,et al.  Yeast hormone response element assays detect and characterize GRIPI coactivator dependent activation of thyroid and retinoid nuclear receptors , 1997 .

[2]  T. Butt,et al.  Yeast hormone response element assays detect and characterize GRIP1 coactivator-dependent activation of transcription by thyroid and retinoid nuclear receptors. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[3]  K. Horwitz,et al.  Nuclear receptor coactivators and corepressors. , 1996, Molecular endocrinology.

[4]  P. Chambon,et al.  TIF2, a 160 kDa transcriptional mediator for the ligand‐dependent activation function AF‐2 of nuclear receptors. , 1996, The EMBO journal.

[5]  S. Yeh,et al.  Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Stallcup,et al.  GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Thorsten Heinzel,et al.  A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors , 1996, Cell.

[8]  R. Evans,et al.  The RXR heterodimers and orphan receptors , 1995, Cell.

[9]  Robert Tjian,et al.  Multiple TAFIIs Directing Synergistic Activation of Transcription , 1995, Science.

[10]  B. O’Malley,et al.  Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily , 1995, Science.

[11]  B. O’Malley,et al.  A nuclear hormone receptor-associated protein that inhibits transactivation by the thyroid hormone and retinoic acid receptors. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Myles Brown,et al.  Polarity-specific activities of retinoic acid receptors determined by a co-repressor , 1995, Nature.

[13]  R. Evans,et al.  A transcriptional co-repressor that interacts with nuclear hormone receptors , 1995, Nature.

[14]  R. Evans,et al.  Interactions between the retinoid X receptor and a conserved region of the TATA-binding protein mediate hormone-dependent transactivation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[15]  P. Kushner,et al.  Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. , 1995, The EMBO journal.

[16]  J. Pike,et al.  Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. , 1995, Molecular endocrinology.

[17]  P. Chambon,et al.  The N‐terminal part of TIF1, a putative mediator of the ligand‐dependent activation function (AF‐2) of nuclear receptors, is fused to B‐raf in the oncogenic protein T18. , 1995, The EMBO journal.

[18]  Y. Sadovsky,et al.  Transcriptional activators differ in their responses to overexpression of TATA-box-binding protein , 1995, Molecular and cellular biology.

[19]  J. Newell,et al.  OBF-1, a novel B cell-specific coactivator that stimulates immunoglobulin promoter activity through association with octamer-binding proteins , 1995, Cell.

[20]  R. Roeder,et al.  Cloning of an intrinsic human TFIID subunit that interacts with multiple transcriptional activators , 1995, Science.

[21]  G. Sprague,,et al.  Protein-protein interactions in the yeast pheromone response pathway: Ste5p interacts with all members of the MAP kinase cascade. , 1994, Genetics.

[22]  X. Jacq,et al.  Human TAFII30 is present in a distinct TFIID complex and is required for transcriptional activation by the estrogen receptor , 1994, Cell.

[23]  M. Stallcup,et al.  Genetic analysis of the N-terminal end of the glucocorticoid receptor hormone binding domain , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[24]  Michael R. Green,et al.  Nuclear protein CBP is a coactivator for the transcription factor CREB , 1994, Nature.

[25]  R. Tjian,et al.  TBP-TAF complexes: selectivity factors for eukaryotic transcription. , 1994, Current opinion in cell biology.

[26]  D. Reinberg,et al.  Interaction of human thyroid hormone receptor beta with transcription factor TFIIB may mediate target gene derepression and activation by thyroid hormone. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Garabedian.  Genetic Approaches to Mammalian Nuclear Receptor Function in Yeast , 1993 .

[28]  K. Yamamoto,et al.  Genetic dissection of the signaling domain of a mammalian steroid receptor in yeast. , 1992, Molecular biology of the cell.

[29]  D. Edwards,et al.  Ligands induce conformational changes in the carboxyl-terminus of progesterone receptors which are detected by a site-directed antipeptide monoclonal antibody. , 1992, Molecular endocrinology.

[30]  B. O’Malley,et al.  Members of the steroid hormone receptor superfamily interact with TFIIB (S300-II). , 1992, The Journal of biological chemistry.

[31]  S. Berger,et al.  Genetic isolation of ADA2: A potential transcriptional adaptor required for function of certain acidic activation domains , 1992, Cell.

[32]  P. Chambon,et al.  Promoter specificity of the two transcriptional activation functions of the human oestrogen receptor in yeast. , 1992, Nucleic acids research.

[33]  J. Lees,et al.  Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. , 1992, The EMBO journal.

[34]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[35]  P. Chambon,et al.  Role of the two activating domains of the oestrogen receptor in the cell‐type and promoter‐context dependent agonistic activity of the anti‐oestrogen 4‐hydroxytamoxifen. , 1990, The EMBO journal.

[36]  S. Watson,et al.  Direct evidence that the glucocorticoid receptor binds to hsp90 at or near the termination of receptor translation in vitro. , 1989, The Journal of biological chemistry.

[37]  S. Watson,et al.  Molecular cloning of a mineralocorticoid (type I) receptor complementary DNA from rat hippocampus. , 1989, Molecular endocrinology.

[38]  K. Yamamoto,et al.  Mutations in the glucocorticoid receptor zinc finger region that distinguish interdigitated DNA binding and transcriptional enhancement activities. , 1989, Genes & development.

[39]  D. Edwards,et al.  Human progesterone receptor complexed with the antagonist RU 486 binds to hormone response elements in a structurally altered form. , 1989, Molecular endocrinology.

[40]  S. Fawell,et al.  Identification of two transactivation domains in the mouse oestrogen receptor. , 1989, Nucleic acids research.

[41]  M. Beato.  Gene regulation by steroid hormones , 1989, Cell.

[42]  R. Evans,et al.  Multiple and cooperative trans-activation domains of the human glucocorticoid receptor , 1988, Cell.

[43]  R. Evans,et al.  The steroid and thyroid hormone receptor superfamily. , 1988, Science.

[44]  J. Shine,et al.  Cloning and expression of full-length cDNA encoding human vitamin D receptor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[45]  F. Galibert,et al.  Complete amino acid sequence of the human progesterone receptor deduced from cloned cDNA. , 1987, Biochemical and biophysical research communications.

[46]  J. Devereux,et al.  A comprehensive set of sequence analysis programs for the VAX , 1984, Nucleic Acids Res..

[47]  B. O’Malley,et al.  Molecular mechanisms of action of steroid/thyroid receptor superfamily members. , 1994, Annual review of biochemistry.

[48]  M. Tzukerman,et al.  Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. , 1994, Molecular endocrinology.